Clinique Pasteur Lanroze
- Address
- lock Available on a paid plan
Digestive System Diseases
Clinique Pasteur Lanroze in Brest conducts a range of studies on cancers of the digestive tract, aiming to improve treatment outcomes and refine diagnostic tools.
- Evaluating immunotherapy combined with chemotherapy for microsatellite stable metastatic colorectal cancer
- Assessing de‑escalation strategies in HER2‑negative gastric and gastro‑oesophageal junction adenocarcinoma
- Testing hyperthermic intraperitoneal chemotherapy in recurrent ovarian epithelial cancer
- Comparing adjuvant mFOLFIRINOX versus single‑agent therapy after resection of ampullary adenocarcinoma
- Investigating ctDNA‑guided adjuvant treatment decisions in colon cancer
The site is involved in 29 clinical trials with 15 investigators, reflecting a strong focus on innovative oncology research in Europe.
Male Urogenital Diseases
The department of Oncology at Clinique Pasteur Lanroze leads multiple trials targeting prostate and bladder malignancies, seeking to enhance therapeutic precision and reduce treatment burden.
- Testing stereotactic radiation combined with darolutamide for oligometastatic castration‑resistant prostate cancer
- Evaluating short‑duration endocrine therapy plus CDK4/6 inhibition guided by ctDNA in hormone‑sensitive prostate cancer
- Assessing PF‑06801591 with BCG for high‑risk non‑muscle invasive bladder cancer
- Comparing intermittent versus continuous androgen deprivation in metastatic hormone‑sensitive prostate cancer
- Studying apalutamide added to salvage radiotherapy after biochemical recurrence post‑prostatectomy
These studies contribute to the 29 active trials at the Brest facility, involving 15 dedicated investigators.
Neoplasms
Across a spectrum of solid tumors, Clinique Pasteur Lanroze explores novel agents and treatment combinations to boost survival and quality of life for patients with advanced disease.
- Evaluating sacituzumab govitecan in triple‑negative metastatic breast cancer
- Assessing HER2‑targeted de‑escalation in HER2‑positive metastatic breast cancer with ctDNA negativity
- Testing ficlatuzumab plus cetuximab versus cetuximab alone in HPV‑negative head and neck squamous cell carcinoma
- Investigating omission of radiotherapy in low‑risk luminal A breast cancer after surgery
- Analyzing pembrolizumab combined with chemotherapy in high‑immune infiltrate colorectal cancer
The centre’s oncology program includes 29 trials led by 15 investigators, emphasizing cutting‑edge research in Europe.
Other Oncology Research
In addition to disease‑specific studies, the site pursues personalized medicine approaches that span multiple cancer types, leveraging biomarkers and innovative drug combinations.
- Developing ctDNA‑guided treatment decisions across various tumor sites
- Exploring gene‑expression driven adjuvant therapy selection in premenopausal breast cancer
- Assessing safety of palbociclib combined with endocrine therapy in hormone‑receptor positive breast cancer
- Evaluating novel androgen‑receptor inhibitors in metastatic castration‑sensitive prostate cancer
- Studying immunotherapy plus radiotherapy in locally advanced head and neck cancer
These initiatives complement the 29 active clinical trials and 15 investigators operating at Clinique Pasteur Lanroze in Brest, France.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 55 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 55 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Clinique Pasteur Lanroze
lock Showing 1 of 36 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 55 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 7 | Unknown | 2014-12-23 | 2026-05-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.